2-Azabicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)-

We are 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)- CAS:866083-42-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-Azabicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)-
CAS.NO:866083-42-3
Synonyms:
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)

Molecular Formula:C6H8N2
Molecular Weight: 108.14100

Physical and Chemical Properties:
Density:/
Boiling point: /
Melting point: /
Flash point:/
Refractive index: /

Specification:
Appearance: Yellow liquid
Purity:≥99%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Saxagliptin CAS:361442-04-8
Intermediates of Saxagliptin hydrochloride CAS:709031-78-7

Related News: The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development.(Methylthio)methylpyrazine The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development.(S)-Methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate CAS:142569-69-5 Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.393-36-2 Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.